Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study

RCT (n=255) reports that in addition to previously reported survival benefits, cabazitaxel improved pain response (46% vs. 19% with abiraterone or enzalutamide; p<0.0001), time to pain progression, time to symptomatic skeletal events, and EQ-5D-5L utility index.


The Lancet Oncology